_JIKK_2024-2.pdf_.png)
2.png)
Literature Review: Cardiac Complication Of Idiopathic Pulmonary Fibrosis
Sari
Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that is associated with radiological and histologic features of usual interstitial pneumonia (UIP). Idiopathic pulmonary fibrosis occurs primarily in adult and associated with poor prognosis with patients typically survive 2-3 years after diagnosis, although some cases progress much faster than others. Symptoms of IPF include cough and shortness of breath, especially during activity. In severe cases, respiratory failure may occur. IPF is often linked to several health problems, including lung cancer, sleep apnea, heart disease, and digestive issues like acid reflux. The cardiovascular problem related to IPF are pulmonary hypertension, coronary artery disease, arrythmia, and iatrogenic disease caused by IPF pharmacological treatment. This literature review will explain the link between IPF and its pathogenesis in causing cardiac complications based on available literature.
Kata Kunci
Teks Lengkap:
PDFReferensi
Abuserewa, S.T., Duff, R. & Becker, G. (2021) Treatment of Idiopathic Pulmonary Fibrosis. Cureus. 13, e15360. doi:10.7759/cureus.15360.
Agrawal, A., Verma, I., Shah, V., Agarwal, A. & Sikachi, R.R. (2016) Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable & Rare Diseases Research. 5, 70–75. doi:10.5582/irdr.2016.01023.
Anderson, L.A., Sinha, S., Durbin, K., Entringer, S., Stewart, J., Thornton, P., Pope, C., Puckey, M., Chao, S. & Hannemann, K. (2023) Warfarin Dosage Guide + Max Dose, Adjustments - Drugs.com. 2023. https://www.drugs.com/dosage/warfarin.html#Usual_Adult_Dose_for_Prevention_of_Thromboembolism_in_Atrial_Fibrillation [Accessed: 13 August 2024].
Beck, R.A. & William M. King, I. (2014) Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation. American Family Physician. 89 (8), 672–675.
Brown, K.K., Rajan, S.K., Shenoy, P., Mehta, M., Lopez, M., Hegde, R.S. & Gogtay, J. (2021) The emerging role of mycophenolate mofetil in interstitial lung diseases. Expert Review of Respiratory Medicine. 15, 1539–1549. doi:10.1080/17476348.2021.2001331.
Budin, C.E., Cocuz, I.G., Sabău, A.H., Niculescu, R., Ianosi, I.R., Ioan, V. & Cotoi, O.S. (2022) Pulmonary Fibrosis Related to Amiodarone—Is It a Standard Pathophysiological Pattern? A Case-Based Literature Review. Diagnostics. 12, 3217. doi:10.3390/diagnostics12123217.
Carr, Z.J., Yan, L., Chavez-Duarte, J., Zafar, J. & Oprea, A. (2022) Perioperative Management of Patients with Idiopathic Pulmonary Fibrosis Undergoing Noncardiac Surgery: A Narrative Review. International Journal of General Medicine. 15, 2087–2100. doi:10.2147/IJGM.S266217.
Farber, H.W., Badesch, D.B., Benza, R.L., Elliott, C.G., Frantz, R.P., McGoon, M.D., Selej, M., Zhao, C. & Frost, A.E. (2018) Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation. 37 (8), 948–955. doi:10.1016/j.healun.2018.03.010.
Gupta, T., Kaur, M. & Sahni, D. (2022) Identification of novel pulmonary vein nodes as generators of ectopic arrhythmic foci for atrial fibrillation: an immunohistochemical proof. Surgical and Radiologic Anatomy. 44, 129–136. doi:10.1007/s00276-021-02864-w.
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., et al.(2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 42, 373–498. doi:10.1093/eurheartj/ehaa612.
Hubbard, R.B., Smith, C., Le Jeune, I., Gribbin, J. & Fogarty, A.W. (2008) The Association between Idiopathic Pulmonary Fibrosis and Vascular Disease: A Population-based Study. American Journal of Respiratory and Critical Care Medicine. 178, 1257–1261. doi:10.1164/rccm.200805-725OC.
Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., et al. (2022) 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 43, 3618–3731. doi:10.1093/eurheartj/ehac237.
Janda, S., Shahidi, N., Gin, K. & Swiston, J. (2011) Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK). p. https://www.ncbi.nlm.nih.gov/books/NBK81537/.
January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C., Conti, J.B., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Murray, K.T., Sacco, R.L., Stevenson, W.G., Tchou, P.J., Tracy, C.M. & Yancy, C.W. (2014) 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 64 (21), e1–e76. doi:10.1016/j.jacc.2014.03.022.
Kizer, J.R., Zisman, D.A., Blumenthal, N.P., Kotloff, R.M., Kimmel, S.E., Strieter, R.M., Arcasoy, S.M., Ferrari, V.A. & Hansen-Flaschen, J. (2004) Association Between Pulmonary Fibrosis and Coronary Artery Disease. Archives of Internal Medicine. 164, 551. doi:10.1001/archinte.164.5.551.
Krishna, R., Chapman, K. & Ullah, S. (2024) Idiopathic Pulmonary Fibrosis. In: StatPearls. Treasure Island (FL), StatPearls Publishing. p. http://www.ncbi.nlm.nih.gov/books/NBK448162/.
Lettieri, C.J., Nathan, S.D., Barnett, S.D., Ahmad, S. & Shorr, A.F. (2006) Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis. Chest. 129, 746–752. doi:10.1378/chest.129.3.746.
Mahida, S., Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France, Sacher, F., Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France, Derval, N., et al. (2015) Science Linking Pulmonary Veins and Atrial Fibrillation. Arrhythmia & Electrophysiology Review. 4 (1), 40. doi:10.15420/aer.2015.4.1.40.
Maron, B.A. (2023) Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. Journal of the American Heart Association. 12, e029024. doi:10.1161/JAHA.122.029024.
Nakamura, Y. & Suda, T. (2015) Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. 9, CCRPM.S39897. doi:10.4137/CCRPM.S39897.
Nathan, S.D., Behr, J., Collard, H.R., Cottin, V., Hoeper, M.M., Martinez, F.J., Corte, T.J., Keogh, A.M., Leuchte, H., Mogulkoc, N., Ulrich, S., Wuyts, W.A., Yao, Z., Boateng, F. & Wells, A.U. (2019) Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. The Lancet Respiratory Medicine. 7, 780–790. doi:10.1016/S2213-2600(19)30250-4.
O’Driscoll, B.R., Howard, L.S., Earis, J. & Mak, V. (2017) British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings. BMJ Open Respiratory Research. 4, 170. doi:10.1136/bmjresp-2016-000170.
Patel, N.M., Lederer, D.J., Borczuk, A.C. & Kawut, S.M. (2007) Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest. 132, 998–1006. doi:10.1378/chest.06-3087.
Peng, J., Xiao, X., Li, S., Lyu, X., Gong, H., Tan, S., Dong, L., Sanders, Y.Y. & Zhang, X. (2023) Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway. Experimental Gerontology. 172, 112085. doi:10.1016/j.exger.2023.112085.
Raghu, G. (2013) Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial. Annals of Internal Medicine. 158, 641. doi:10.7326/0003-4819-158-9-201305070-00003.
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C.C., Inoue, Y., et al. (2022) Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 205, e18–e47. doi:10.1164/rccm.202202-0399ST.
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y.Y., Ding, Q., Antony, V.B., Zhang, J., Zmijewski, J. & Thannickal, V.J. (2016) Novel Mechanisms for the Antifibrotic Action of Nintedanib. American Journal of Respiratory Cell and Molecular Biology. 54 (1), 51–59. doi:10.1165/rcmb.2014-0445OC.
Richeldi, L., Du Bois, R.M., Raghu, G., Azuma, A., Brown, K.K., et al. (2014) Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 370, 2071–2082. doi:10.1056/NEJMoa1402584.
Roh, S.-Y., Choi, J.-I., Lee, J.Y., Kwak, J.-J., Park, J.-S., Kim, J.-B., Lim, H.-E. & Kim, Y.-H. (2011) Catheter Ablation of Atrial Fibrillation in Patients With Chronic Lung Disease. Circulation: Arrhythmia and Electrophysiology. 4, 815–822. doi:10.1161/CIRCEP.110.960435.
Scholand, M., Wolff, R., Crossno, P., Sundar, K., Winegar, M., Whipple, S., Carey, P., Sunchild, N. & Coon, H. (2014) Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough. 10, 3. doi:10.1186/1745-9974-10-3.
Seyyedi, S.R., Sharif-Kashani, B., Sadr, M., Chitsazan, M., Malekmohammad, M., Abedini, A., Monjazebi, F. & Naghashzadeh, F. (2019) The Relationship between Electrocardiographic Changes and Prognostic Factors in Severely Symptomatic Pulmonary Hypertension. Tanaffos. 18 (1), 34–40.
Sinha, R., Nanavaty, D., Azhar, A., Devarakonda, P., Singh, S., Garikipati, R., Sanghvi, A., Manoharan, S., Parhar, G., Zaman, K., Ayala-Rodriguez, C., Vasudevan, V., Reddy, S. & Gerolemou, L. (2024) A Step towards understanding coronary artery disease: a complication in idiopathic pulmonary fibrosis. BMJ Open Respiratory Research. 11, e001834. doi:10.1136/bmjresp-2023-001834.
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. New England Journal of Medicine. 366, 1968–1977. doi:10.1056/NEJMoa1113354.
Vahdatpour, C.A., Luebbert, J.J. & Palevsky, H.I. (2020) Atrial arrhythmias in chronic lung disease‐associated pulmonary hypertension. Pulmonary Circulation. 10, 1–13. doi:10.1177/2045894020910685.
Waxman, A., Restrepo-Jaramillo, R., Thenappan, T., Ravichandran, A., Engel, P., Bajwa, A., Allen, R., Feldman, J., Argula, R., Smith, P., Rollins, K., Deng, C., Peterson, L., Bell, H., Tapson, V. & Nathan, S.D. (2021) Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. New England Journal of Medicine. 384, 325–334. doi:10.1056/NEJMoa2008470.
Wolters, P.J., Collard, H.R. & Jones, K.D. (2014) Pathogenesis of Idiopathic Pulmonary Fibrosis. Annual Review of Pathology: Mechanisms of Disease. 9, 157–179. doi:10.1146/annurev-pathol-012513-104706.
Ye, Y., Xu, Q. & Wuren, T. (2023) Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension. Frontiers in Immunology. 14, 1162556. doi:10.3389/fimmu.2023.1162556.
Zappala, C.J., Latsi, P.I., Nicholson, A.G., Colby, T.V., Cramer, D., Renzoni, E.A., Hansell, D.M., Du Bois, R.M. & Wells, A.U. (2010) Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. European Respiratory Journal. 35 (4), 830–836. doi:10.1183/09031936.00155108.
Zhang, W.-T., Wang, X.-J., Xue, C.-M., Ji, X.-Y., Pan, L., Weng, W.-L., Li, Q.-Y., Hua, G.-D. & Zhu, B.-C. (2021) The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 12, 771804. doi:10.3389/fphar.2021.771804.
DOI: https://doi.org/10.33024/jikk.v11i12.17722
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc4.footer##
Pendidikan Dokter Universitas Malahayati Lampung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.